MedTrace Logo

Lesogaberan in Chinese Patients With Refractory Reflux Symptoms

NCT02818309 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2016-06-29

No results posted yet for this study

Summary

Lesogaberan may be used in Chinese GERD patients with partial response to PPI.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

Lesogaberan

120 mg bid

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Ministry of Science and Technology, Taiwan

    collaborator OTHER_GOV

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Ping-Huei Tseng, MD, PhD · National Taiwan University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-11-30
Completion
2017-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02818309 on ClinicalTrials.gov